Neurocrine Biosciences | NBIX - Current Liabilities


Neurocrine Biosciences reported $638M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 39.39B 376M Sep/2025
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agios Pharmaceuticals USD 74.76M 4.35M Sep/2025
ALKERMES USD 474.36M 31.6M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
Biogen USD 3.29B 106.3M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Cytokinetics USD 142.14M 11.08M Sep/2025
Dynavax Technologies USD 106.84M 11.39M Sep/2025
Exelixis USD 373.78M 37.67M Sep/2025
Gilead Sciences USD 12.3B 1.11B Sep/2025
Halozyme Therapeutics USD 837.23M 702.95M Sep/2025
Incyte USD 1.34B 60.11M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Neurocrine Biosciences USD 638M 91.7M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Prothena USD 51.44M 16.37M Sep/2025
Regeneron Pharmaceuticals USD 4.43B 758.1M Sep/2025
Repligen USD 131.14M 8.12M Sep/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Teva Pharmaceutical Industries USD 13.46B 1.96B Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025